The docetaxel debate: impact of chemotherapy in high-risk non-metastatic prostate cancer

Taxanes have an established role in the management of metastatic prostate cancer (1-5) but much controversy still exists in their application for men with high risk non-metastatic disease. Much of this controversy is due to the varied settings in which they have been studied as for instance primary treatment with radiation and androgen deprivation therapy vs. post-prostatectomy and by wide ranging risk factors such as node positive disease, Gleason score, elevated PSA, or T3/T4 disease.